TY - JOUR
T1 - NTS-Polyplex
T2 - A potential nanocarrier for neurotrophic therapy of Parkinson's disease
AU - Martinez-Fong, Daniel
AU - Bannon, Michael J.
AU - Trudeau, Louis Eric
AU - Gonzalez-Barrios, Juan A.
AU - Arango-Rodriguez, Martha L.
AU - Hernandez-Chan, Nancy G.
AU - Reyes-Corona, David
AU - Armendáriz-Borunda, Juan
AU - Navarro-Quiroga, Ivan
N1 - Funding Information:
This review article was supported by the Consejo Nacional de Ciencia y Tecnología de México Grant # 83229 (D.M-F.), Instituto Científico Pfizer (D.M-F.), Canadian Institutes of Health Research Grants OPD-79574 , MOP-49591 and MOP-106556 (L.E.T.), Parkinson Society Canada (L.E.T.), and National Institutes of Health Grant DA006470 (M.J.B.). M.L.A-R., N.G.H-C, and D. R-C were recipients of scholarships from the Consejo Nacional de Ciencia y Tecnología de México.
PY - 2012/10
Y1 - 2012/10
N2 - Nanomedicine has focused on targeted neurotrophic gene delivery to the brain as a strategy to stop and reverse neurodegeneration in Parkinson's disease. Because of improved transfection ability, synthetic nanocarriers have become candidates for neurotrophic therapy. Neurotensin (NTS)-polyplex is a "Trojan horse" synthetic nanocarrier system that enters dopaminergic neurons through NTS receptor internalization to deliver a genetic cargo. The success of preclinical studies with different neurotrophic genes supports the possibility of using NTS-polyplex in nanomedicine. In this review, we describe the mechanism of NTS-polyplex transfection. We discuss the concept that an effective neurotrophic therapy requires a simultaneous effect on the axon terminals and soma of the remaining dopaminergic neurons. We also discuss the future of this strategy for the treatment of Parkinson's disease. From the Clinical Editor: This review paper focuses on nanomedicine-based treatment of Parkinson's disease, a neurodegenerative condition with existing symptomatic but no curative treatment. Neurotensin-polyplex is a synthetic nanocarrier system that enables delivery of genetic cargo to dopaminergic neurons via NTS receptor internalization.
AB - Nanomedicine has focused on targeted neurotrophic gene delivery to the brain as a strategy to stop and reverse neurodegeneration in Parkinson's disease. Because of improved transfection ability, synthetic nanocarriers have become candidates for neurotrophic therapy. Neurotensin (NTS)-polyplex is a "Trojan horse" synthetic nanocarrier system that enters dopaminergic neurons through NTS receptor internalization to deliver a genetic cargo. The success of preclinical studies with different neurotrophic genes supports the possibility of using NTS-polyplex in nanomedicine. In this review, we describe the mechanism of NTS-polyplex transfection. We discuss the concept that an effective neurotrophic therapy requires a simultaneous effect on the axon terminals and soma of the remaining dopaminergic neurons. We also discuss the future of this strategy for the treatment of Parkinson's disease. From the Clinical Editor: This review paper focuses on nanomedicine-based treatment of Parkinson's disease, a neurodegenerative condition with existing symptomatic but no curative treatment. Neurotensin-polyplex is a synthetic nanocarrier system that enables delivery of genetic cargo to dopaminergic neurons via NTS receptor internalization.
KW - Neurodegeneration
KW - Neuroprotection
KW - Neurorestoration
KW - Regeneration
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84866503164&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2012.02.009
DO - 10.1016/j.nano.2012.02.009
M3 - Articulo en revista no especializada
C2 - 22406187
AN - SCOPUS:84866503164
SN - 1549-9634
VL - 8
SP - 1052
EP - 1069
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 7
ER -